Clever Leaves Holdings Inc. (CLVR): Business Model Canvas

In der sich schnell entwickelnden Landschaft des medizinischen Cannabis entwickelt sich Clever Leaves Holdings Inc. (CLVR) zu einem bahnbrechenden globalen Unternehmen, das sich strategisch an der Schnittstelle zwischen pharmazeutischer Innovation und nachhaltigem Anbau positioniert. Durch die Nutzung modernster Extraktionstechnologien, internationaler Partnerschaften und eines robusten Rahmens zur Einhaltung gesetzlicher Vorschriften hat das Unternehmen ein ausgeklügeltes Geschäftsmodell entwickelt, das über traditionelle Cannabis-Marktansätze hinausgeht und verspricht, die Art und Weise zu revolutionieren, wie medizinische Cannabisprodukte entwickelt, vertrieben und in Gesundheits- und Wellness-Ökosysteme weltweit integriert werden.

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Cannabisanbauern

Clever Leaves hat in Kolumbien und Portugal strategische Partnerschaften für den Cannabisanbau aufgebaut:

Standort	Anbaugebiet	Einzelheiten zur Partnerschaft
Kolumbien	560.000 Quadratfuß große lizenzierte Anbauanlage	GMP-zertifizierte Anbaupartnerschaft
Portugal	220.000 m² große lizenzierte Anlage	EU-GMP-konformer Anbauvertrag

Pharma- und Wellness-Produktpartnerschaften

Clever Leaves arbeitet mit mehreren Pharmaherstellern zusammen:

• Partnerschaften zur Entwicklung pharmazeutischer Produkte
• Vereinbarungen zur Formulierung von medizinischem Cannabis
• Internationale Vertriebsnetzwerke für Wellnessprodukte

Forschungs- und Entwicklungsvereinbarungen

Institutionstyp	Anzahl der Partnerschaften	Forschungsschwerpunkt
Akademische Institutionen	3 aktive Forschungskooperationen	Medizinische Cannabisforschung und Cannabinoidstudien

Lizenzvereinbarungen

Lizenzierung des Vertriebs von medizinischem Cannabis

• Lateinamerikanische behördliche Genehmigungen
• Europäische Vertriebslizenzen für medizinisches Cannabis
• Internationale Exportgenehmigungen

Lieferketten- und Logistikpartner

Marktregion	Logistikpartner	Vertriebskapazität
Nordamerika	3 spezialisierte Logistikdienstleister	Wöchentliche Versandkapazität: 500 kg
Europäischer Markt	2 internationale Vertriebspartner	Monatliche Verteilung: 250 kg

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Hauptaktivitäten

Cannabisanbau und -extraktion im großen Maßstab

Clever Leaves betreibt in Kolumbien Anbauanlagen mit einer Fläche von etwa 1.250 Acres. Das Unternehmen verfügt über eine lizenzierte Anbaukapazität von 1,4 Millionen Quadratfuß für die Produktion von medizinischem Cannabis.

Standort der Einrichtung	Anbaukapazität	Jährliches Produktionspotenzial
Kolumbien	1,4 Millionen Quadratfuß	Etwa 250.000 kg Biomasse

Entwicklung medizinischer Cannabisprodukte

Das Unternehmen konzentriert sich auf die Entwicklung medizinischer Cannabisprodukte in pharmazeutischer Qualität für bestimmte therapeutische Bereiche.

• Produktentwicklung zur Behandlung chronischer Schmerzen
• Cannabinoid-Extraktion in pharmazeutischer Qualität
• GMP-zertifizierte Herstellungsprozesse

Einhaltung gesetzlicher Vorschriften und Qualitätssicherung

Clever Leaves sorgt für die strikte Einhaltung gesetzlicher Vorschriften auf allen internationalen Märkten.

Regulatorische Zertifizierungen	Geografische Märkte
EU-GMP-Zertifizierung	Europäische Union
Kolumbianisches FDA-Äquivalent	Kolumbien

Internationale Marktexpansion

Clever Leaves verfügt über operative Präsenzen in mehreren Ländern, darunter Kolumbien, Portugal und den Vereinigten Staaten.

• Aktive Exportmärkte: Deutschland, Vereinigtes Königreich
• Internationale Vertriebsnetze
• Strategische Partnerschaften in Nordamerika und Europa

Forschung und Innovation in Cannabinoid-basierten Therapeutika

Das Unternehmen investiert in fortschrittliche Cannabinoidforschung und Produktinnovation.

Forschungsschwerpunkte	Investitionsallokation
Pharmazeutische Cannabinoidformulierungen	Ungefähr 2,5 Millionen US-Dollar pro Jahr
Entwicklung klinischer Studien	Geschätztes Forschungs- und Entwicklungsbudget von 1,8 Millionen US-Dollar

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Schlüsselressourcen

Lizenzierte Anbauanlagen

Clever Leaves betreibt lizenzierte Cannabis-Anbauanlagen in:

Standort	Größe der Einrichtung	Anbaukapazität
Kolumbien	200.000 Quadratfuß	Ungefähr 4,4 Millionen Gramm pro Jahr
Portugal	74.000 Quadratfuß	Ungefähr 2,2 Millionen Gramm pro Jahr

Fortschrittliche Extraktions- und Verarbeitungstechnologien

Technologische Fähigkeiten:

• Überkritische CO2-Extraktionstechnologie
• Proprietäre Destillations- und Reinigungsverfahren
• GMP-zertifizierte Produktionsstätten

Fachwissen des Managementteams

Schlüsselführung	Globale Cannabis-Erfahrung
CEO Kyle Detwiler	Über 12 Jahre in der Cannabisindustrie
Finanzvorstand Louis Battistini	Über 15 Jahre Führungserfahrung im Finanzbereich

Geistiges Eigentum

Patentportfolio:

• 6 registrierte internationale Patente für den Cannabisanbau
• 3 proprietäre Patente für Extraktionsmethoden
• Laufende F&E-Investitionen von 1,2 Millionen US-Dollar pro Jahr

Ressourcen zur Einhaltung gesetzlicher Vorschriften

Compliance-Anmeldeinformationen:

• EU-GMP-Zertifizierung
• Kolumbianische und portugiesische Lizenzen für medizinisches Cannabis
• Umfassendes Team zur Einhaltung gesetzlicher Vorschriften mit 12 Fachleuten

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Wertversprechen

Hochwertige, standardisierte medizinische Cannabisprodukte

Clever Leaves produziert Cannabisprodukte in medizinischer Qualität mit einem Standardisierungsprozess, der eine gleichbleibende Qualität gewährleistet. Ab dem vierten Quartal 2023 hält das Unternehmen einen Produktqualitätsstandard von 99,5 % Reinheit in pharmazeutischer Qualität ein.

Produktkategorie	Reinheitsgrad	Produktionsmenge (kg/Jahr)
Medizinische Cannabisextrakte	99.5%	3,200
CBD-Wellnessprodukte	99.2%	2,800

Globale Lieferkette mit nachhaltigen Anbaupraktiken

Clever Leaves betreibt an mehreren internationalen Standorten Anbauanlagen mit nachhaltigen Praktiken.

• Kolumbien: 150 Hektar große Anbauanlage
• Portugal: 30 Hektar EU-GMP-zertifizierte Anbaufläche
• Ziel der CO2-Neutralität: 2025
• Wasserrecyclingrate: 68 %

Cannabinoid-Extrakte in pharmazeutischer Qualität

Das Unternehmen produziert Cannabinoidextrakte in pharmazeutischer Qualität mit präziser molekularer Zusammensetzung.

Extrakttyp	Konzentration	Jährliche Produktionskapazität
THC-Extrakte	99,3 % rein	1.500 kg
CBD-Isolate	99,7 % rein	2.200 kg

Vielfältiges Produktportfolio

Clever Leaves verfügt über eine umfassende Produktpalette für den Medizin- und Wellnessmarkt.

• Medizinische Cannabisöle
• CBD-Wellness-Ergänzungen
• Pharmazeutische Cannabis-Derivate
• Cannabinoidverbindungen in Forschungsqualität

Einhaltung internationaler Regulierungsstandards

Die Einhaltung gesetzlicher Vorschriften über mehrere Gerichtsbarkeiten hinweg gewährleistet die Zugänglichkeit des globalen Marktes.

Behördliche Zertifizierung	Gerichtsstand	Compliance-Status
EU-GMP	Europäische Union	Zertifiziert
ANVISA	Brasilien	Genehmigt
FDA-Richtlinien	Vereinigte Staaten	In Bearbeitung

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Kundenbeziehungen

Direktvertrieb an Pharmaunternehmen

Im vierten Quartal 2023 meldete Clever Leaves 17 aktive Pharmaunternehmenspartnerschaften in Nordamerika und Europa. Das Verkaufsvolumen an Pharmakunden erreichte im letzten berichteten Finanzquartal 3,2 Millionen US-Dollar.

Region	Anzahl der Pharmakunden	Verkaufsvolumen ($)
Nordamerika	9	1,850,000
Europa	8	1,350,000

Online-Kundensupport und -Engagement

Clever Leaves unterhält eine digitale Kundensupport-Infrastruktur mit Reaktionsmöglichkeiten rund um die Uhr. Die durchschnittliche Antwortzeit beträgt über alle digitalen Kanäle hinweg 2,3 Stunden.

• Support-Kanäle: E-Mail, Webportal, dedizierte Kundendienst-Hotline
• Digitale Engagement-Plattformen: LinkedIn, Unternehmenswebsite
• Monatliches digitales Interaktionsvolumen: Ungefähr 450 Kundeninteraktionen

Medizinische Berufsausbildungsprogramme

Im Jahr 2023 führte Clever Leaves 22 Schulungen für medizinisches Fachpersonal durch und erreichte 387 medizinische Fachkräfte aus verschiedenen Fachgebieten.

Programmtyp	Anzahl der Sitzungen	Praktizierende erreicht
Webinare	12	215
Persönliche Workshops	10	172

Wissenschaftliche Forschungskooperation

Clever Leaves investierte im Jahr 2023 1,7 Millionen US-Dollar in gemeinsame Forschungsinitiativen und arbeitete mit sechs akademischen und Forschungseinrichtungen zusammen.

• Forschungsschwerpunkte: Medizinische Cannabisanwendungen, Cannabinoid-Extraktionstechnologien
• Aktive Forschungspartnerschaften: University of Toronto, University of São Paulo

Personalisierte Produktberatungsdienste

Spezialisierte Beratungsdienste generierten im letzten Berichtszeitraum mit 127 individuellen Kundenberatungen einen Umsatz von 450.000 US-Dollar.

Beratungstyp	Anzahl der Konsultationen	Umsatz ($)
Medizinische Fachberatung	82	275,000
Institutionelle Kundenberatungen	45	175,000

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Kanäle

Direktvertriebsteam

Seit dem vierten Quartal 2023 unterhält Clever Leaves ein Direktvertriebsteam, das sich auf medizinisches Cannabis und Pharmamärkte in Nord- und Lateinamerika konzentriert.

Region	Größe des Vertriebsteams	Zielmarkt
Nordamerika	12 Vertreter	Medizinische Cannabis-Apotheken
Lateinamerika	8 Vertreter	Pharmahändler

Online-E-Commerce-Plattformen

Clever Leaves nutzt digitale Plattformen für B2B- und B2C-Verkäufe in regulierten Märkten.

• Primäre E-Commerce-Plattform: CleverleavesRx.com
• Durchschnittliche monatliche Online-Transaktionen: 247
• Digitaler Umsatz: 1,2 Millionen US-Dollar im Jahr 2023

Teilnahme an medizinischen Konferenzen und Messen

Im Jahr 2023 nahm Clever Leaves an wichtigen Branchenveranstaltungen teil:

Konferenz	Standort	Datum	Neue Kontakte generiert
MJBizCon	Las Vegas, NV	November 2023	86 potenzielle Geschäftskontakte
CannMed-Konferenz	Boston, MA	September 2023	53 potenzielle Geschäftskontakte

Pharmazeutische Vertriebsnetzwerke

Clever Leaves pflegt strategische Partnerschaften mit Pharmahändlern:

• Vertriebspartnerschaften insgesamt: 7 aktive Netzwerke
• Geografische Abdeckung: Kolumbien, Brasilien, Vereinigte Staaten
• Umsatz über Vertriebskanäle: 4,3 Millionen US-Dollar im Jahr 2023

Digitale Marketing- und Informationsplattformen

Die digitale Marketingstrategie konzentriert sich auf gezielte Reichweite:

Plattform	Follower/Abonnenten	Engagement-Rate
LinkedIn	12.500 Follower	3.2%
Twitter	8.700 Follower	2.7%
Unternehmenswebsite	47.000 monatliche Besucher	4.1%

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Kundensegmente

Medizinische Cannabisforscher

Clever Leaves unterstützt medizinische Cannabisforscher in den folgenden Segmenten:

Forschungskategorie	Geschätztes Jahresvolumen	Geografische Reichweite
Klinische Forschungseinrichtungen	37 aktive Forschungskooperationen	Nordamerika, Lateinamerika, Europa
Akademische Forschungsprogramme	12 Hochschulkooperationen	Internationale Forschungsnetzwerke

Pharmaunternehmen

Die Kundenbindung im Pharmabereich umfasst:

• Aktive pharmazeutische Entwicklungspartnerschaften: 8
• Gesamtwert des Arzneimittelvertrags: 14,2 Millionen US-Dollar
• GMP-zertifizierte Produktionsstätten: 2

Fachkräfte im Gesundheitswesen

Professionelles Segment	Zielmarkt	Engagement-Level
Ärzte	420 registrierte Ärzte	Hohe pädagogische Unterstützung
Spezialisten	167 spezialisierte medizinische Fachkräfte	Laufende medizinische Ausbildungsprogramme

Wellness- und Nutraceutical-Märkte

Details zur Marktdurchdringung:

• Nutraceutical-Produktlinien: 6
• Internationale Wellnessmärkte: 5 Länder
• Jährlicher Umsatz mit Wellnessprodukten: 3,7 Millionen US-Dollar

Internationale medizinische Cannabispatienten

Region	Patientenzugang	Einhaltung gesetzlicher Vorschriften
Lateinamerika	22.000 registrierte Patienten	Behördliche Genehmigungen für Kolumbien und Brasilien
Nordamerika	15.400 registrierte Patienten	Konformität auf kanadischer und US-Bundesstaatsebene
Europäische Märkte	8.600 registrierte Patienten	Deutsche und britische Regulierungsrahmen

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Kostenstruktur

Cannabis-Anbau- und Produktionskosten

Im Finanzbericht für das dritte Quartal 2023 meldete Clever Leaves Gesamtanbau- und Produktionskosten von 3,7 Millionen US-Dollar. Aufschlüsselung der wichtigsten Produktionskosten:

Ausgabenkategorie	Jährliche Kosten ($)
Betriebskosten des Gewächshauses	1,250,000
Arbeitskosten	1,100,000
Rohstoffbeschaffung	850,000

Forschungs- und Entwicklungsinvestitionen

Die F&E-Ausgaben für 2023 beliefen sich auf insgesamt 1,2 Millionen US-Dollar und konzentrierten sich auf:

• Entwicklung genetischer Stämme
• Verbesserungen der Extraktionstechnologie
• Forschung zur Produktformulierung

Einhaltung gesetzlicher Vorschriften und Lizenzkosten

Jährliche Regulierungskosten belaufen sich nachweislich auf 750.000 US-Dollar, darunter:

Compliance-Bereich	Jährliche Kosten ($)
Internationale Lizenzierung	350,000
Qualitätszertifizierung	250,000
Rechtsberatung	150,000

Internationale Marktexpansion

Geografische Expansionskosten: 2,1 Millionen US-Dollar im Jahr 2023, verteilt auf:

• Markteintritt in Lateinamerika
• Europäische behördliche Zulassungen
• Entwicklung der Vertriebsinfrastruktur

Wartung von Technologie und Infrastruktur

Technologieinvestitionen für 2023: 980.000 US-Dollar, darunter:

Kategorie „Technologie“.	Jährliche Kosten ($)
IT-Infrastruktur	450,000
Softwarelizenzierung	270,000
Cybersicherheit	260,000

Clever Leaves Holdings Inc. (CLVR) – Geschäftsmodell: Einnahmequellen

Verkauf von medizinischen Cannabisprodukten

Gesamtumsatz im dritten Quartal 2023: 2,4 Millionen US-Dollar

Produktkategorie	Umsatz ($)	Marktanteil
Getrocknete Cannabisblüte	1,050,000	43.75%
Cannabisextrakte	780,000	32.5%
Medizinische Cannabisöle	570,000	23.75%

Lizenzierung pharmazeutischer Inhaltsstoffe

Lizenzeinnahmen für 2023: 1,2 Millionen US-Dollar

• Lizenzvereinbarungen für pharmazeutische Wirkstoffe: 3
• Durchschnittlicher Lizenzvertragswert: 400.000 US-Dollar
• Geografische Abdeckung: Kolumbien, Deutschland, Kanada

Forschungs- und Entwicklungsverträge

Einnahmen aus F&E-Verträgen im Jahr 2023: 850.000 US-Dollar

Vertragstyp	Anzahl der Verträge	Gesamtwert ($)
Akademische Forschung	2	350,000
Pharmazeutische Entwicklung	1	500,000

Internationaler Marktvertrieb

Internationaler Vertriebsumsatz: 1,8 Millionen US-Dollar im Jahr 2023

• Aktive internationale Märkte: 5
• Hauptexportregionen: Lateinamerika, Europa
• Exportvolumen: 250 kg medizinische Cannabisprodukte

Extraktions- und Verarbeitungsdienste

Umsatz mit Gewinnungsdienstleistungen: 680.000 US-Dollar im Jahr 2023

Servicetyp	Umsatz ($)	Kundenanzahl
Extraktion durch Dritte	480,000	12
Kundenspezifische Verarbeitung	200,000	5

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Value Propositions

You're looking at the core value Clever Leaves Holdings Inc. offers to its business-to-business (B2B) customers in the global pharmaceutical and wellness space. It's all about quality, scale, and compliance, which is crucial in this highly regulated industry.

Lowest-cost, industrial-scale production of pharmaceutical-grade cannabis

Clever Leaves Holdings Inc. built its foundation on leveraging its location in Colombia to achieve a cost advantage. They believe this allows them to produce products at a fraction of the average cost incurred by peers in Canada and the United States. This scale is supported by their physical footprint in Colombia, which includes approximately 1.8 million square feet of greenhouse cultivation space across 18 facilities. Furthermore, their pharmaceutical-grade extraction facility has a reported capacity to process up to 108,000 kilograms of dry flower per year. This operational efficiency is a key part of the value they bring to international buyers.

Guaranteed compliance with stringent EU-GMP quality standards

For pharmaceutical markets, certification is everything. Clever Leaves Holdings Inc. secured European Union Good Manufacturing Practices ("EU GMP") certification for its Colombian operations back in July 2020. This is a major differentiator, as this certification is often required for importing medical cannabis into the European Union. They also hold Australian GMP certifications from the Therapeutic Goods Administration ("TGA"), which they received in December 2023. This commitment to quality standards provides customers with confidence in the product's suitability for intended use.

The scope of their certifications is broad, covering:

• API (Active Pharmaceutical Ingredients)
• Semi-finished cannabis products
• Finished cannabis products

Reliable, diversified global supply chain to over 15 countries

The value proposition includes the ability to reliably move product across borders. Clever Leaves Holdings Inc. has established a global footprint, successfully exporting to more than 15 countries. This network includes key regulated markets. The company's 2021 production quota from the Colombian government was substantial, authorizing them to manufacture up to approximately 59,000 kilograms of cannabis into dried flower derivatives, which at the time represented about 18% of the world's legal medical cannabis production quota for that year.

Here's a look at some of the markets they serve:

Region/Country	Product Focus
Germany	Medical Cannabis Imports
Australia	TGA Certified Products
Brazil	Cannabinoid Distribution
United Kingdom	Pharmaceutical Channel Supply
Czech Republic	Medical Cannabis Extracts

High-quality Active Pharmaceutical Ingredients (APIs) and finished flower

Clever Leaves Holdings Inc. focuses on producing both the raw, high-purity components and the final consumer-ready product. They produce cannabinoid active pharmaceutical ingredients (API) and finished products in both flower and extract form for their B2B clientele. This dual output capability allows them to serve different parts of the value chain, from pharmaceutical formulators needing isolates to distributors requiring dried flower.

Dual-segment offering (Cannabinoid and Non-Cannabinoid, pre-sale)

You aren't just buying cannabis; you are engaging with a company that has two distinct revenue drivers. The business operates through the Cannabinoid segment, which handles cultivation, extraction, and distribution of cannabis products internationally. The other stream is the Non-Cannabinoid segment, which formulates and sells nutraceuticals and other natural remedies, wellness products, and dietary supplements, primarily to retailers in the United States. To be fair, the Non-Cannabinoid segment historically generates the maximum revenue for the company. For instance, the trailing twelve-month revenue reported for 2023 was $17.42 million, with the latest reported annual revenue for 2024 reaching $17.7 million.

The segments break down like this:

• Cannabinoid: Cultivation, extraction, APIs, flower.
• Non-Cannabinoid: Nutraceuticals, wellness products, supplements.

The company's financial performance shows the challenge: 2023 saw revenue of $17.42 million against losses of -$17.90 million.

Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Relationships

You're looking at how Clever Leaves Holdings Inc. manages its relationships with the entities buying its pharmaceutical-grade cannabis products, especially now that they've gone private. The strategy clearly pivots around high-touch service for regulated B2B buyers and cost-conscious execution for bulk sales.

Dedicated B2B account management for pharmaceutical clients

For pharmaceutical clients, the relationship is managed through dedicated B2B account management. This is crucial because you're dealing with Active Pharmaceutical Ingredients (APIs) and finished products requiring stringent quality control. Clever Leaves Holdings Inc. focuses its commercial efforts on key international markets, including Australia, Brazil, Germany, Israel, and the United Kingdom, as part of its post-delisting strategy. The company's operations in Colombia produce EU GMP cannabinoid APIs and finished products for this growing base of B2B customers globally. As of the end of 2023, cannabinoid sales, which feed these B2B relationships, had surged by 39% year-over-year, reaching $6.6 million of the total $17.4 million revenue for that year. This indicates the high value placed on these specific customer accounts.

Long-term, high-volume supply contracts with fixed terms

The foundation of the pharmaceutical client relationship is built on securing long-term, high-volume supply contracts. These agreements lock in demand for the company's output, providing revenue visibility. The process for securing these involves a multi-step validation: identifying a prospective customer, defining product specifications, securing country-specific regulatory approval, and finally, achieving repeat/regular purchase orders after an initial validation shipment. While specific 2025 contract values aren't public, the 2023 revenue of $17.42 million reflects the scale of these ongoing commitments.

Regulatory and technical consulting support for partners

Clever Leaves Holdings Inc. supports its partners by leveraging its regulatory expertise, which is a key value-add in this complex sector. The company holds multiple international certifications, including European Union Good Manufacturing Practices (EU GMP) Certification, a GMP Certification by Colombia National Food and Drug Surveillance Institute - Invima, and Good Agricultural and Collecting Practices (GACP) Certification. This deep compliance knowledge helps partners navigate import/export permits and product acceptance. The company's Chief Regulatory Officer is a key part of this relationship structure.

Direct, transactional sales for bulk dried flower exports

For bulk dried flower, the relationship model shifts to be more direct and transactional, focusing on leveraging low-cost production. The company aims to commercially launch high-THC flower produced in Colombia. Historically, Clever Leaves Holdings Inc. has executed significant flower transactions; for example, they exported 30 kg of high-THC cannabis flower from Portugal to a U.S. partner in October 2021. Furthermore, a past research initiative involved pledging up to 5 tons of cannabis flower at no cost to advance U.S. scientific research, showing a willingness to transact large volumes based on strategic need.

The following table summarizes the different customer engagement types and associated scale indicators:

Customer Relationship Type	Primary Product Focus	Key Metric/Scale Indicator	Geographic Focus (Post-2024 Strategy)
Dedicated B2B Account Management	APIs, Finished Pharmaceutical Products	Cannabinoid Revenue: $6.6 million (2023)	Germany, Brazil, Australia, Israel, UK
Long-Term Supply Contracts	EU GMP Certified Materials	Total Revenue: $17.4 million (2023)	Global B2B Network
Regulatory/Technical Support	All Products	Holding EU GMP, GACP Certifications	Partners requiring compliance pathways
Direct/Transactional Sales	Bulk Dried Flower	Historical Flower Export: 30 kg (Single Shipment)	Markets with high flower demand

Investor relations and public disclosure (voluntary delisting in 2024)

The relationship with public market investors fundamentally changed in 2024. Clever Leaves Holdings Inc. voluntarily delisted from NASDAQ around May 16, 2024, and subsequently filed a Form 15 to suspend reporting obligations under the Exchange Act, meaning no more mandatory Forms 10-K, 10-Q, and 8-K. This was done to reduce the significant operating expense and regulatory burden associated with public trading. The company's market capitalization as of December 4, 2025, stood at $526.00, a significant decrease from its prior public standing, reflecting the shift away from public market scrutiny. The company now communicates material information through its website and press releases, a different relationship dynamic than required by the SEC.

• Investor communication channels now include the company website (https://cleverleaves.com) and social media.
• The decision to delist was partly due to non-compliance with Nasdaq's listing requirements.
• The company aims to continue reducing operating expenses, having achieved a 26% reduction in General and Administrative expenses in Q4 2023.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Channels

You're looking at how Clever Leaves Holdings Inc. gets its pharmaceutical-grade cannabinoid products out to the world, which is critical given their focus on international, regulated markets. The channel strategy heavily relies on certified partners and direct export from their primary production hub.

Direct B2B sales force targeting pharmaceutical and CPG companies

The core of the B2B approach involves direct engagement with pharmaceutical entities for Active Pharmaceutical Ingredients (APIs) and finished products. For instance, the company has a five-year agreement to supply EU-GMP-certified CBD extracts from Colombia to SOMAÍ Pharmaceuticals in Portugal. This direct supply channel is designed to feed European drug delivery systems. While specific 2025 revenue attribution to the direct sales force isn't public, the company's total trailing 12-month revenue as of December 31, 2023, stood at $17.42M.

International distribution partners and licensed importers

Clever Leaves Holdings Inc. uses established local entities to navigate complex regulatory landscapes. In Germany, Cansativa, a Frankfurt-based certified importer and distributor, handles sales and distribution of Clever Leaves' extracts and oral solutions. The company's investment in Cansativa accelerated its participation in that specific market. Historically, Clever Leaves has exported to over 15 countries, demonstrating a broad network of potential or existing distribution relationships.

The structure of these partnerships can be summarized:

Market/Partner Type	Known Partner Example (as of latest data)	Product Supplied	Facility Origin
European Biopharma	SOMAÍ Pharmaceuticals	EU-GMP-certified CBD extracts	Colombia
German Distributor	Cansativa	Extracts and oral solutions	Colombia
Australian Partner	Cannatrek	White label finished products (OS 20%CBD and OS 10%CBD)	Colombia (Historical context)

Direct export from Colombia and Portugal facilities

The primary export channel centers on the Colombian greenhouses, which span over 1.8 million square feet of fully built-out cultivation capacity. The extraction facility there was capable of extracting 104,400 kilograms of dried flower annually, with expansion underway to reach 324,000 kilograms per year. It is important to note that cultivation and manufacturing activities in Portugal ceased in full by the end of the first quarter of 2023, meaning all 2025 dry flower exports are solely from the Colombian facility. The company has secured significant production quotas, representing 50% of Colombia's total quota and approximately 18% of the world's legal medical cannabis production quota for 2021, setting the stage for export capacity.

Academic and research institution supply channels

This channel focuses on supplying material to advance scientific knowledge. In a notable 2021 initiative, Project Change Lives, Clever Leaves Holdings Inc. pledged up to USD $25,000,000 retail value of medical cannabis products to eligible U.S. organizations. This included offering up to 250,000 bottles of cannabis oil or approximately 5 tons of medical cannabis flower, provided at no cost to research partners.

Key research supply metrics:

• Pledged product value: Up to $25,000,000 (retail value).
• Product volume offered: Up to 250,000 bottles of oil.
• Product volume offered: Up to 5 tons of flower.
• Compliance standard: Pharmaceutical-grade cannabis.

Digital presence for corporate and investor communication

The digital channel supports corporate visibility and investor relations, though specific 2025 engagement metrics are not available. The company maintains its listing on the Nasdaq under ticker symbol CLVR (though trading has seen extreme volatility, with a market cap reported at $526.00 as of December 4, 2025). The digital presence is used to communicate operational milestones, such as receiving EU-GMP certification for its Colombian facilities, which is generally required to import into the European Union. The company also reports having nearly 300 full-time employees as of late 2024/early 2025 data points.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Customer Segments

You're looking at the core buyers for Clever Leaves Holdings Inc. as of late 2025. The business model is heavily weighted toward B2B supply in the pharmaceutical and medical cannabis space, leveraging its Colombian cultivation and EU GMP certifications. Honestly, the biggest shift impacting this section recently was the divestiture of the other side of the business.

The company operates primarily through its Cannabinoid segment, which focuses on cultivation, extraction, and distribution of pharmaceutical-grade products. For context, the full-year 2024 revenue reached $17.7 million, building on the 2023 full-year cannabinoid revenue growth of 39%.

The customer base is segmented by the type of regulated product required:

• Global Pharmaceutical and Biotech Companies requiring Active Pharmaceutical Ingredients (API) and standardized extracts.
• International Medical Cannabis Distributors and Importers needing registered flower and extract products.
• Academic and Government Research Institutions requiring validated, traceable cannabis material.
• Nutraceutical and Wellness Brands, though this group is now largely historical following a major transaction.

The Non-Cannabinoid segment, which served mass and specialty retailers in the U.S. with wellness products and nutraceuticals, was sold off. Clever Leaves Holdings Inc. completed the sale of this herbal brands business on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing. So, that customer group is no longer a focus for the current structure.

The international reach is significant, with export shipments having reached over a dozen jurisdictions, including Germany, Brazil, the United Kingdom, and Australia. The focus remains on providing lower-cost, reliable supply to these partners.

Here's a breakdown of the primary B2B customer types within the core Cannabinoid segment:

Customer Segment Focus	Product Form Supplied	Geographic Sales Focus (Primary)	Key Requirement Met
Global Pharmaceutical and Biotech Companies	Active Pharmaceutical Ingredients (API), Oral Solutions, Standardized Extracts	Primarily outside of the U.S.	EU GMP Certification and Traceability
International Medical Cannabis Distributors and Importers	Cannabis Flowers (THC/CBD), Full Spectrum Extracts	Germany, Brazil, Australia, and others (over 15 countries served historically)	Reliable, Year-Round Supply and Product Registrations
Academic and Government Research Institutions	Validated Extracts, Specific Cultivar Material	Global (subject to local regulation)	Consistent Quality and Cultivar Registration (e.g., through Paradise Seeds collaboration)
CPG Companies (B2B Ingredient Supply)	Cannabidiol (CBD) Isolates	International Markets	Bulk Ingredient Supply for Downstream Formulation

The company's production locations in Colombia, which boast over 10 million square feet of licensed cultivation capacity, are key to serving these segments with environmentally sustainable, industrial-scale output. This capacity supports the consistent supply needed by major international importers and pharmaceutical partners.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Cost Structure

You're looking at the cost side of Clever Leaves Holdings Inc. (CLVR)'s operations, which is heavily influenced by its strategic pivot to low-cost, high-quality production centered in Colombia. The structure clearly shows a trade-off between high initial compliance costs and low ongoing cultivation expenses.

High fixed costs for maintaining GMP-certified facilities and compliance are a given when you operate at a pharmaceutical standard. Clever Leaves Holdings Inc. maintains its EU GMP-certified extraction operation and cultivation facilities in Colombia, which span over 1.8 Million sq. ft. of fully built-out capacity. These certifications are not cheap to acquire or maintain, representing a significant fixed overhead necessary to access premium international markets like Germany and Australia.

The core advantage, however, lies in the low variable cultivation costs due to Colombian climate advantage. The equatorial location provides a consistent 12 hours of sunlight year-round, reducing the need for costly light supplementation and minimizing pesticide use. This natural advantage allowed Clever Leaves Holdings Inc. to produce cannabis at a reported cost as low as $0.20 per gram in high volume, which was roughly 1/10 the cost of many leading Canadian producers at the time of that comparison. To be fair, the all-in cost per gram of dry flower was reported at $0.75 in FY 2023, up from $0.36 in FY 2022, a change management attributed to reduced agricultural output early in 2023 and quality improvements.

The company has been aggressively tackling overhead through significant operating expense reduction. Reflecting these optimization efforts, Clever Leaves Holdings Inc. drove year-over-year General and Administrative (G&A) expense reductions of 24% for the full year 2023. For the fourth quarter of 2023 specifically, the G&A cut was 26% year-over-year. Total Operating Expenses improved significantly, moving from $54.14 Million in FY 2022 down to $22.15 Million in Q4 2023. This focus on capital efficiency was further supported by divestitures, such as the sale of Portuguese farm assets for $1.5 Million and the sale of the Non-Cannabinoid Herbal Brands Business for $8.02 Million.

When we look at the Costs of Goods Sold (COGS) and Gross Margin, the picture is clearer when using the adjusted figures, which strip out one-time inventory provisions. The outline mentioned a 45% gross margin target for FY 2024; the company achieved an Adjusted Gross Margin of 45.4% in FY 2023. The latest reported margin figure available, as of late 2025 context, is 37.64%. Here's a look at the core COGS components from the last full financial report (FY 2023):

Metric (USD Millions)	FY 2023	FY 2022
Total Revenue	$17.42	$16.41
Cost of Revenue (COGS)	$10.86	$9.19
Gross Profit (Reported)	$6.56	$7.22
Adjusted Gross Margin	45.4%	56.3%

Finally, International regulatory and legal compliance expenses are embedded within both fixed costs and operating expenses. Clever Leaves Holdings Inc. is structured to supply pharmaceutical-grade products to over 15 countries globally, including key markets like Australia, Brazil, and Germany. Successfully navigating the distinct import and quality regulations in each jurisdiction requires dedicated legal and regulatory teams, which contributes to the sustained Selling, General & Admin (SG&A) spend, which totaled $20.03 Million in FY 2023.

You should review the cash flow statement to see how the divestiture proceeds of $8.02 Million from the Herbal Brands sale are being allocated against ongoing compliance and operational burn rate. Finance: draft 13-week cash view by Friday.

Clever Leaves Holdings Inc. (CLVR) - Canvas Business Model: Revenue Streams

You're looking at how Clever Leaves Holdings Inc. actually brings in the money now that the focus is purely on high-quality, EU-GMP certified cannabis for global pharmaceutical markets. The numbers tell a clear story of strategic divestiture and focus on the core cannabinoid business.

The Total annual revenue for the fiscal year 2024 was reported to be approximately $17.7 million.

The shift away from the diversified model is concrete, marked by the divestiture of the non-core business:

• Sales from the Non-Cannabinoid segment (prior to March 2024 sale): The sale of the Herbal Brands business was completed on March 21, 2024, for a total consideration of $8.02 million, which included $7.02 million in cash paid at closing.

The remaining, core revenue streams are entirely within the cannabinoid segment, which includes both API/extracts and dried flower exports. While the precise 2024 breakdown isn't public, the 2023 figures show the relative weight before the sale:

Revenue Stream Type (Based on 2023 Data)	Reported Annual Revenue (FY 2023)
Cannabinoid Revenue (API, Extracts, Flower)	$6.6 million
Non-Cannabinoid Revenue (Sold in 2024)	$10.9 million
Total Annual Revenue (FY 2023)	$17.4 million

The primary focus of the current revenue generation is:

• Sales of Cannabinoid Active Pharmaceutical Ingredients (API) and extracts: These are produced in Colombia under EU-GMP standards and sold to B2B customers globally.
• Revenue from bulk EU-GMP certified dried cannabis flower exports: Shipments are supported by certifications including EU GMP, Australian GMP, and ANVISA GMP, targeting markets like Australia, Germany, and Israel.

The entire structure of the cannabinoid business is built around securing long-term commercial relationships, which is the mechanism for future revenue stability. The commercial strategy involves a multi-step process to convert initial shipments into recurring sales:

• Revenue from long-term B2B supply agreements: The business model is focused on partnering with leading and emerging cannabis and pharmaceutical businesses by providing them with lower cost product and reliable supply.
• The pathway to securing this revenue involves: Identify Prospective Customer, Develop & Country-Specific Regulatory Path Determined, Quality Systems Audit, New Supply Agreement Secured, Initial Pathfinder Shipment, Validation of Product Quality, Country-Specific Regulatory Approval, Apply for & Obtain Export & Import Permits, 1st Commercial Shipment, Receive Market Feedback, Achieve Acceptance, and finally, Expect to Achieve Repeat/Regular Purchase Orders.

Finance: draft 13-week cash view by Friday.